SCHEMBL4901656

SCHEMBL4901656

[CH2]Cn1cnc(C(=O)O)c1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PLA2G4A P47712 1/20 0.39
KDM4E B2RXH2 5/20 0.38
SMYD3 Q9H7B4 1/20 0.34
RBP4 P02753 1/20 0.33
KDM5A P29375 2/20 0.33
KDM5B Q9UGL1 2/20 0.33
P4HTM Q9NXG6 3/20 0.32
NAPRT Q6XQN6 2/20 0.32
LMNA P02545 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
HCAR2 Q8TDS4 1/20 0.32
KDM4C Q9H3R0 1/20 0.32
USP30 Q70CQ3 2/20 0.32
P4HA1 P13674 1/20 0.31
MIF P14174 1/20 0.31
ALOX15 P16050 1/20 0.31
TSHR P16473 1/20 0.31
ACMSD Q8TDX5 1/20 0.31
TDP1 Q9NUW8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28726420 0.82 ADA (0.42) SMYD3LMNAUSP30TSHR
SCHEMBL3689829 0.82 PLA2G4A (0.40) PLA2G4AKDM4ESMYD3RBP4KDM5A
SCHEMBL3690823 0.80 PLA2G4A (0.39) PLA2G4AKDM4ESMYD3RBP4KDM5A
SCHEMBL151394 0.80 SMYD3 (0.50) PLA2G4AKDM4ESMYD3RBP4KDM5A
SCHEMBL4590582 0.80 PLA2G4A (0.42) PLA2G4AKDM4ESMYD3RBP4KDM5A
SCHEMBL31650910 0.79 PLA2G4A (0.37) PLA2G4AKDM4ESMYD3RBP4KDM5A
SCHEMBL7265607 0.78 PLA2G4A (0.39) PLA2G4AKDM4ESMYD3RBP4KDM5A
SCHEMBL5730751 0.78 SMYD3 (0.43) SMYD3USP30
SCHEMBL4891287 0.78 MEN1 (0.44) KDM4ESMYD3L3MBTL1
SCHEMBL710279 0.77 KDM5A (0.54) PLA2G4AKDM4ESMYD3KDM5AKDM5B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080242656-A1 N-Substituted-N-Sulfonylaminocyclopropane Compounds and Pharmaceutical Use Thereof JAPAN TOBACCO INC. 2008-10-02 US disclosed
US-20050222146-A1 N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof JAPAN TOBACCO INC. (JP) 2005-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242656-A1 N-Substituted-N-Sulfonylaminocyclopropane Compounds and Pharmaceutical Use Thereof MMP13, MMP11, MMP3 PLA2G4A 1199/4885KDM4E 2523/4885SMYD3 1003/4885
US-20050222146-A1 N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof MMP13, MMP11, MMP1 PLA2G4A 1174/4885KDM4E 2481/4885SMYD3 921/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.